Profile data is unavailable for this security.
About the company
Alkem Laboratories Limited is an India-based company, which is engaged in the pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company offers its products across various therapeutic areas, such as Anti Infective, Dermatology, Diabetology, Cardiology, Gastroenterology, Osteoporosis, Rheumatology, central nervous system (CNS), Oncology, Urology, Gynecology, and Vitamins, Mineral and Nutrition. Its product range includes Rx Products, Alkem Generics and OTC Product. The Company’s product portfolio includes brands, such as Clavam, Pan, Pan-D, Taxim-O, A To Z NS, Xone, Taxim, Gemcal, Pipzo and Ondem. The Company operates through a segment, Pharmaceuticals. It has approximately 21 manufacturing facilities at multiple locations in India and the United States. The Company has approximately 800 brands and operates in 40 countries.
- Revenue in INR (TTM)126.34bn
- Net income in INR15.73bn
- Incorporated1973
- Employees16.87k
- LocationAlkem Laboratories LtdAlmac House, Senapati Bapat MargMUMBAI 400013IndiaIND
- Phone+91 2 239829999
- Fax+91 2 224927190
- Websitehttps://www.alkemlabs.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IPCA Laboratories Ltd | 71.86bn | 5.64bn | 339.02bn | 16.17k | 60.07 | -- | 36.22 | 4.72 | 22.25 | 22.25 | 283.32 | -- | -- | -- | -- | 4,444,876.00 | -- | 11.95 | -- | 15.34 | 65.47 | 59.17 | 8.45 | 13.77 | -- | 12.99 | -- | 12.02 | 7.11 | 13.72 | -46.69 | 14.51 | 29.32 | 51.57 |
| GlaxoSmithKline Pharmaceuticals Limited | 33.11bn | 5.29bn | 352.80bn | 3.68k | 66.69 | -- | 59.03 | 10.65 | 31.23 | 31.23 | 195.53 | -- | -- | -- | -- | 8,998,269.00 | -- | 9.94 | -- | 16.01 | 60.37 | 54.71 | 15.97 | 11.58 | -- | 447.28 | -- | 196.13 | -0.8025 | 2.35 | 59.58 | 11.62 | -35.79 | 12.83 |
| Biocon Ltd | 146.13bn | 12.00bn | 359.76bn | 3.41k | 29.97 | -- | 11.93 | 2.46 | 10.03 | 10.03 | 122.21 | -- | -- | -- | -- | 42,877,050.00 | -- | 4.31 | -- | 5.91 | 67.17 | 61.34 | 10.19 | 10.87 | -- | 1.66 | -- | 8.49 | 36.54 | 22.03 | -28.64 | 4.44 | 13.50 | 24.57 |
| Alkem Laboratories Ltd | 126.34bn | 15.73bn | 615.63bn | 16.87k | 39.13 | -- | 32.94 | 4.87 | 131.58 | 131.58 | 1,056.65 | -- | -- | -- | -- | 7,488,804.00 | -- | 11.44 | -- | 17.01 | 59.75 | 58.84 | 12.46 | 13.31 | -- | 5.83 | -- | 30.96 | 9.08 | 12.52 | -40.19 | 9.30 | -19.38 | 13.97 |
| Aurobindo Pharma Ltd | 278.95bn | 27.70bn | 681.56bn | 15.69k | 24.62 | -- | 15.92 | 2.44 | 47.25 | 47.25 | 475.59 | -- | -- | -- | -- | 17,778,640.00 | -- | 9.84 | -- | 14.92 | 55.29 | 53.05 | 9.92 | 13.06 | -- | 23.89 | -- | 8.33 | 5.97 | 8.54 | -27.21 | -4.47 | 12.20 | 3.71 |
| Lupin Ltd | 194.80bn | 17.91bn | 765.50bn | 18.97k | 42.86 | -- | 27.21 | 3.93 | 39.19 | 39.19 | 426.18 | -- | -- | -- | -- | 10,268,360.00 | -- | 0.2337 | -- | 0.3443 | 64.99 | 58.56 | 9.29 | 0.3673 | -- | 6.89 | -- | 470.26 | 1.44 | 1.04 | 128.15 | 11.35 | -0.7025 | -4.36 |
| Mankind Pharma Ltd | 99.46bn | 17.27bn | 916.05bn | 18.47k | 53.08 | -- | 42.87 | 9.21 | 43.08 | 43.08 | 248.12 | -- | -- | -- | -- | 5,385,717.00 | -- | -- | -- | -- | 68.37 | -- | 17.68 | -- | -- | 144.35 | -- | -- | 12.44 | -- | -10.58 | -- | -- | -- |
| Torrent Pharmaceuticals Ltd | 104.74bn | 15.03bn | 919.62bn | 13.57k | 61.14 | -- | 40.00 | 8.78 | 44.44 | 44.44 | 309.68 | -- | -- | -- | -- | 7,716,901.00 | -- | 6.70 | -- | 10.48 | 74.12 | 70.84 | 14.35 | 11.22 | -- | 6.32 | -- | 63.62 | 13.07 | 10.09 | 60.22 | 12.92 | -6.22 | 25.74 |
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 31 Mar 2024 | 2.89m | 2.42% |
| ICICI Prudential Asset Management Co. Ltd.as of 30 Apr 2024 | 2.75m | 2.30% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 2.04m | 1.70% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 1.92m | 1.61% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 1.87m | 1.56% |
| HDFC Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Mar 2024 | 1.40m | 1.17% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Mar 2024 | 1.06m | 0.89% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 1.05m | 0.88% |
| SBI Funds Management Ltd.as of 31 Mar 2024 | 1.02m | 0.85% |
| Kotak Mahindra Asset Management (Singapore) Pte Ltd.as of 30 Jun 2023 | 974.21k | 0.82% |
